Corticosteroids in uveitis.

Area of Science:

• Ophthalmology
• Inflammatory Diseases
• Pharmacology

Background:

• Corticosteroids (CS) are widely used for intraocular inflammation, particularly noninfectious uveitis.
• Current evidence for CS efficacy in treating visual loss from uveitis is limited.
• The long-term benefits and risks of CS in uveitis remain inadequately established.

Purpose of the Study:

• To evaluate the existing evidence on the effectiveness of corticosteroids in managing visual loss associated with intraocular inflammation.
• To identify limitations in current research regarding corticosteroid use in uveitis.
• To highlight the need for rigorous clinical trials to determine optimal corticosteroid treatment strategies.

Main Methods:

• Systematic review of existing literature on corticosteroid efficacy in uveitis.
• Analysis of case series data, noting the absence of randomized clinical trials.
• Identification of methodological limitations in current studies, including lack of control groups and quality of life assessments.

Main Results:

• No strong evidence from randomized clinical trials supports the effectiveness of CS in treating visual loss from intraocular inflammation.
• Case series suggest CS may prevent visual loss in acute noninfectious uveitis, but long-term efficacy is unknown.
• Severe adverse effects of chronic CS use and lack of quality of life data are significant limitations.

Conclusions:

• Current evidence is insufficient to definitively answer questions about corticosteroid effectiveness for visual loss in intraocular inflammation.
• Due to adverse effects and unknown long-term efficacy, CS should be used acutely and tapered, with CS-sparing agents for prolonged treatment.
• Randomized clinical trials are essential to establish the short- and long-term effectiveness of CS in uveitis.